Viropharma Announces Completion Of Enrollment In Phase 3 St

**Curis helping to treat cancer, neurological degenerative, kidney disorders, CUDC-101. Pathways, hedgehog, EGFR, Her2, Hsp90, Bcr-Abl/Src, CDK, BCL, MEK, VEGF, HDAC.**

Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Stem Cell Research News
Reply to topic
Viropharma Announces Completion Of Enrollment In Phase 3 St
RSS FEED


Joined: 05 Apr 2006
Posts: 19275
Post Posted: Thu Jun 05, 2008 8:22 am Reply with quote
ViroPharma Incorporated (Nasdaq: VPHM) announced that it completed enrollment in its pivotal Phase 3 study of maribavir in stem cell transplant patients. This international Phase 3 study is evaluating the efficacy, safety and tolerability of prophylactic use of maribavir administered orally for up to 12 weeks for the prevention of cytomegalovirus (CMV) disease in recipients of allogeneic stem cell transplants (SCT).

Read more...
View user's profileSend private message
Viropharma Announces Completion Of Enrollment In Phase 3 St
All times are GMT - 7 Hours  
Page 1 of 1  
  
  
Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Stem Cell Research News
 Reply to topic  
Forum Map
Site Map